SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — John Locke — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientJohn Locke
Date of birth1632-09-08
IdentifiersMRN HR-EN001-SYN-TD; SSN (made up) 000-01-8305
Document date1692-03-26
AuthorPrudence Hartwell-Osei, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Two-week review of lung function and blood tests; pulmonology consultation today. [S]

History of Present Illness

Mr. Locke returns two weeks after his first visit. He has used albuterol once or twice a day, and not since early this morning, six hours before his tests. The open fires in his rooms have not been lit since his first visit; the household has put electric heaters in his study and bedroom, and a HEPA air cleaner runs in each. He has stayed in the country and checks the air quality index each morning. His night cough has eased to two nights a week, but he is still breathless on stairs and hills and wheezes in the cold. He has had no fever, weight loss, night sweats, or blood in his sputum. This morning he had full lung function tests, a six-minute walk, and a CT of the chest, and saw Dr. Nwankwo-Fairfax of pulmonology. [S]

ElementDetail
Reliever useAlbuterol once or twice a day; withheld six hours before testing
ExposureNo open fires since intake; electric heating; HEPA air cleaners running; no city trips
SymptomsNight cough two nights a week; breathless on stairs and hills
Asthma Control Test13, up from 12

Review of Systems

SystemResultFinding
ConstitutionalNegativeNo fever, night sweats, or weight loss
Ears, nose, mouth, and throatNegativeNo nasal blockage, postnasal drip, or loss of smell
RespiratoryPositiveCough at night two nights a week, wheeze in cold air, breathless on exertion; no hemoptysis
CardiovascularNegativeNo chest pain, ankle swelling, or breathlessness lying flat
GastrointestinalNegativeNo heartburn or acid regurgitation

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Albuterol 90 mcg/actuation inhaler, two puffs every 4 hours as needed while tests are done; hold for 6 hours before spirometryTwo puffs every 4 hours as neededRespiratory tract route1692-03-12 to 1692-03-26completedS
Budesonide-formoterol 160/4.5 mcg inhaler as maintenance and reliever (GINA track 1, step 4): two inhalations twice daily and one inhalation as needed for symptoms, no more than 12 inhalations a dayTwo inhalations twice daily plus one as needed; no more than 12 a dayRespiratory tract route1692-03-26activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1692-03-26Body height178cmS
1692-03-26Body weight62.1kgS
1692-03-26Body mass index (BMI) [Ratio]19.6kg/m2S
1692-03-26Systolic blood pressure120mm[Hg]S
1692-03-26Diastolic blood pressure74mm[Hg]S
1692-03-26Heart rate82/minS
1692-03-26Respiratory rate18/minS
1692-03-26Body temperature36.5CelS
1692-03-26Oxygen saturation in Arterial blood by Pulse oximetry95%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1692-03-26FEV1 --pre bronchodilation2.11LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-03-26Forced vital capacity [Volume] Respiratory system by Spirometry --pre bronchodilation3.71LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
1692-03-26FEV1/FVC0.57{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cmLowS
1692-03-26FEV1 measured/predicted62%GLI Global race-neutral equations for a man of 59, 178 cmLowS
1692-03-26FEV1 --post bronchodilation2.49LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 3.38 LLowS
1692-03-26Forced vital capacity [Volume] Respiratory system --post bronchodilation4.02LLower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; predicted 4.37 LNormalS
1692-03-26FEV1/FVC --post bronchodilation0.62{ratio}Lower limit of normal, GLI Global race-neutral equations for a man of 59, 178 cm; below it (and below 0.70) after bronchodilator means persistent airflow limitationLowS
1692-03-26Diffusion capacity.carbon monoxide26.4mL/min/mm[Hg]Lower limit of normal, GLI 1683 race-neutral equations; predicted 26.9NormalS
1692-03-26Fractional concentration of exhaled nitric oxide41[ppb]In adults, below 25 ppb low, 25 to 50 intermediate, above 50 high (ATS)HighS
1692-03-26Six minute walk test430mPredicted about 630 m for his age, sex, height and weight (Enright and Sherrill); lower limit about 480 mLowS
1692-03-26Total score [ACT]13{score}S

Physical Exam

Vital signs recorded on 1692-03-26; see the Vital Signs section. [S]

SystemFinding
GeneralThin, comfortable at rest
RespiratoryProlonged expiration with scattered expiratory wheeze; no crackles; no clubbing; oxygen saturation 95 percent
CardiovascularRegular rhythm; no murmur; jugular venous pressure not raised; no edema

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic cough with wheeze and breathlessness since his late thirties, worse every winter and within a day of any stay in the city or by an open fire, better in warm weather and country air; night cough two or three times a week this winter; under evaluationresolvedconfirmed R05.3S — Synthetic presenting problem echoing his documented lifelong cough and breathlessness in London's coal smoke; superseded by the diagnosis at the second visit.
Long exposure to urban air pollution (decades in a large city with heavy traffic and coal and wood burning) and to indoor solid-fuel smoke from open coal and wood fires at homeactiveconfirmed Z77.110S — Synthetic modern exposure echoing the coal smoke that he, Sydenham, and Lady Masham blamed for his cough; no historical level of exposure is asserted.
Asthma with persistent airflow limitation, type 2 (eosinophilic) phenotype, in a never-smoker: post-bronchodilator FEV1/FVC 0.62, FEV1 62 percent predicted rising 380 mL after albuterol, FeNO 41 ppb, eosinophils 0.46 x 10^3/uL, IgE 186 IU/mL, normal DLCO, no emphysema on CT; aggravated by air pollution and indoor smoke; not COPDactiveconfirmed J45.40S — Synthetic modern diagnosis. His lifelong cough and breathlessness worse in coal smoke are documented (D); calling them asthma is a modern retrospective reading (R).

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
SurveyAsthma Control TestEvery visitCompleted today13, up from 12; still very poorly controlled
ImagingSpirometry before and after bronchodilator (FEV1, FVC, FEV1/FVC, bronchodilator response)At diagnosis, 3 to 6 months after starting treatment, then every 1 to 2 yearsCompleted todayFEV1 2.11 L before (62 percent predicted) and 2.49 L after albuterol (+380 mL); FVC 3.71 L before and 4.02 L after; FEV1/FVC 0.57 before and 0.62 after, below the lower limit of normal; GLI Global race-neutral equations
ImagingFeNOWhen the diagnosis is uncertain, and to monitor inhaled-corticosteroid responseCompleted today41 ppb, intermediate, before any inhaled corticosteroid
ImagingDiffusing capacity (DLCO)Once, for persistent airflow limitationCompleted today26.4 mL/min/mmHg, normal
ImagingSix-minute walk testBefore and after pulmonary rehabilitationCompleted today430 m, below the lower limit of about 480 m; lowest saturation 94 percent
LaboratoryBlood eosinophils and total IgEAt diagnosis and at any severe-asthma workupCompleted todayResults from the first visit reviewed today: eosinophils 0.46 x 10^3/uL; IgE 186 IU/mL
LaboratoryAlpha-1 antitrypsin levelOnce, for persistent airflow limitationCompleted todayResult from the first visit reviewed today: 131 mg/dL, normal
ImagingChest imaging (X-ray; CT)Chest X-ray or CT only for atypical features or a suspected complicationCompleted todayChest X-ray at the first visit clear; CT today for persistent airflow limitation in a never-smoker: airway wall thickening and air trapping, no emphysema, bronchiectasis, or nodules
ExaminationInhaler technique with his own devicesEvery visitCompleted todayTaught today with his new budesonide-formoterol inhaler; correct by teach-back
Medication safetyAdherence and reliever useEvery visitCompleted todayAlbuterol once or twice a day until today, when it is stopped and replaced by budesonide-formoterol as needed
SurveyExacerbation history (oral corticosteroid courses, emergency visits, admissions in the past 12 months)Every visitCompleted todayNone
Self-managementTrigger and exposure review: indoor solid-fuel smoke, outdoor air pollution and air quality alerts, tobacco and vaping, occupational exposures, allergensEvery visitCompleted todayOpen fires out of use since intake; electric heating; HEPA air cleaners in his study and bedroom; air quality index checked each morning; no city trips since intake
Self-managementSmoking and vaping statusEvery visitCompleted todayNever smoker; no vaping; no secondhand smoke
Self-managementWritten asthma action planEvery visit and after every flareCompleted todayFirst written plan given today, symptom-based; peak-flow zones to be added once his personal best is known
Medication safetyStep-up and step-down assessmentEvery visitCompleted todayStarted at GINA track 1, step 4 (medium-dose budesonide-formoterol maintenance and reliever) for very poorly controlled asthma with low lung function
ExaminationComorbidity surveillance: rhinitis and sinus disease, reflux, obesity, sleep apnea, vocal cord dysfunction, anxiety and depressionAt diagnosis and at least yearlyUp to dateScreened at the first visit: no rhinitis, reflux, or snoring; BMI 19.6; PHQ-2 1
ReferralPulmonary rehabilitationFor persistent breathlessness or reduced exercise capacityOrderedEight-week program starting next week
ReferralPulmonology consultationFor diagnostic uncertainty or persistent airflow limitationCompleted todaySeen today; agrees with asthma with persistent airflow limitation and the plan
Self-managementVaccination statusYearlyCompleted todayPCV20 today; influenza, COVID-19, and RSV vaccines due in the autumn; Tdap up to date
Medication safetyBiologic candidacyWhen asthma is severe and uncontrolled despite optimized step 4 to 5 treatment with confirmed adherence and techniqueNot indicatedNo exacerbations needing oral corticosteroids and not uncontrolled on optimized treatment

Goal progress:

Immunizations given today: Pneumococcal conjugate vaccine PCV20 [S]

Guideline basis: CMID: Clinical Monitoring Intelligence Database, asthma and COPD monographs (2026); Global Strategy for Asthma Management and Prevention, 2025 update (2025); 2020 Focused Updates to the Asthma Management Guidelines: A Report from the National Asthma Education and Prevention Program Coordinating Committee Expert Panel Working Group (2020); Global Strategy for the Prevention, Diagnosis and Management of COPD: 2025 Report (2025); Stanojevic S, et al. ERS/ATS technical standard on interpretive strategies for routine lung function tests. Eur Respir J 2022;60(1):2101499 (PMID 34949706) (2022); Bhakta NR, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official American Thoracic Society Statement. Am J Respir Crit Care Med 2023;207(8):978-995 (PMID 36973004) (2023); Pulmonary Rehabilitation for Adults with Chronic Respiratory Disease: An Official American Thoracic Society Clinical Practice Guideline (2023); WHO global air quality guidelines: particulate matter (PM2.5 and PM10), ozone, nitrogen dioxide, sulfur dioxide and carbon monoxide (2021); Carlsten C, et al. Personal strategies to minimise effects of air pollution on respiratory health: advice for providers, patients and the public. Eur Respir J 2020;55(6):1902056 (PMID 32241830) (2020); AQI Basics (2026); Air Cleaners and Air Filters in the Home (2026); Adult Immunization Schedule by Age (2026)

Follow-up: Asthma review in twelve weeks with repeat spirometry and FeNO; call sooner if the reliever is needed more than usual. Next scheduled visit 1692-06-18: twelve-week asthma review with repeat spirometry after pulmonary rehabilitation. [S]